Axplora invests $30 million in lyophilization at Le Mans site, boosting ADC production. Facilities enhance control, reliability, and traceability.

Axplora has announced an investment to expand lyophilization capabilities at its Le Mans site, strengthening its ability to deliver reliable, efficient and fast ADC manufacturing for customers.

WuXi XDC Cayman Inc. has entered a strategic collaboration with Earendil Labs on WuXi XDC's proprietary WuXiTecan-2 payload-linker technology platform.

The interest in the potential of antibody-drug conjugates (ADC) continues to grow among some of pharma’s biggest players. Bristol Myers Squibb (BMS) announced Thursday morning that it has entered into ...

License from Synaffix focuses on bispecific ADCs This close collaboration between ABL Bio and Synaffix provides optimal conditions to accelerate research and development of resulting next-generation ...

Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...

Lyophilization, or freeze-drying, is essential in biopharmaceutical production but presents significant challenges, such as long timelines, high prices, and ...

Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), licensed its ADC technology to BigHat Biosciences ...